Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: A Phase I, randomized, single-dose, dose-escalation study

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 28, Issue 2, 2015, Pages 106-115

  Stass, Heino ^a   Delesen, Heinz ^a   Nagelschmitz, Johannes ^a   Staab, Doris ^b  

^a BAYER PHARMA AG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Ciprofloxacin DPI; Cystic fibrosis; long term treatment; lung targeting; Pseudomonas aeruginosa

Indexed keywords

CIPROFLOXACIN; PLACEBO; ANTIINFECTIVE AGENT; POWDER;

ADULT; AIRWAY OBSTRUCTION; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; BRONCHUS OBSTRUCTION; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRY POWDER; DYSGEUSIA; FEMALE; FEVER; FORCED EXPIRATORY FLOW; HEADACHE; HUMAN; HYPOTENSION; LUNG FUNCTION TEST; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; NAUSEA; PARESIS; PARESTHESIA; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SORE THROAT; SPUTUM ANALYSIS; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VERTIGO; ADOLESCENT; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; DRY POWDER INHALER; GERMANY; INHALATIONAL DRUG ADMINISTRATION; LUNG; MEDICINAL CHEMISTRY; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PATHOPHYSIOLOGY; POWDER; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SPUTUM; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CIPROFLOXACIN; CYSTIC FIBROSIS; DRY POWDER INHALERS; FEMALE; GERMANY; HUMANS; LUNG; MALE; POWDERS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SINGLE-BLIND METHOD; SPUTUM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84926286104     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2013.1056     Document Type: Article

References (17)

1. Cystic Fibrosis Trust: Antibiotic Treatment for Cystic Fibrosis. Third edition. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group. Available at: http://www .cftrust.org.uk/aboutcf/publications/consensusdoc/Antibiotic-treatment-for-Cystic-Fibrosis.pdf. Accessed July 29, 2011.
2. Stass H, Baumann-Noss S, Delesen H, Nagelschmitz J, Willmann S, and Edginton A: Ciprofloxacin PulmoSphere-inhalational powder: A healthy volunteer study. Presented at the American Thoracic Society International Conference, Toronto, Canada, May 16-21, 2008. Poster G50.
3. Heijerman H, Westerman E, Conway S, Touw D, and Doring G: Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J Cyst Fibros. 2009;8:295-315.
4. Chalkley LJ, and Koornhof HJ: Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: Antibiotic comparisons and synergistic interactions. Antimicrob Agents Chemother. 1985;28:331-342.
5. Geller DE, Weers J, and Heuerding S: Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J Aerosol Med Pulm Drug Deliv. 2011;24:175-182.
6. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, and Yernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5-40.
7. Stass H, Nagelschmitz J, Kappeler D, and Weimann B: Lung deposition of ciprofloxacin dry powder for inhalation in healthy subjects and patients suffering from chronic obstructive pulmonary disease or non-cystic fibrosis bronchiectasis. [Poster]. Presented at the International Congress of the American Thoracic Society, Philadelphia, PA, USA, May 19, 2013.
8. Peloquin CA, Cumbo TJ, Nix DE, Sands MF, and Schentag JJ: Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med. 1989;149:2269-2273.
9. Endermann R, Labischinski H, Ladel C, Petersen U, and Newton B: Treatment of bacterial diseases of the respiratory organs: US 2004/0254194 A1 Patent. 2004.
10. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, and Geller DE: Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER Trial. J Cyst Fibros. 2011;10:54-61.
11. Alothman GA, Ho B, Alsaadi MM, Ho SL, O'Drowsky L, Louca E, and Coates AL: Bronchial constriction and inhaled colistin in cystic fibrosis. Chest. 2005;127:522-529.
12. European Committee on Antimicrobial Susceptibility Testing: Breakpoint tables for interpretation of MICs and zone diameters. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Disk-test-documents/EUCAST-breakpoints-v1.3-pdf. Accessed July 29, 2011.
13. Schentag JJ, Gilliland KK, and Paladino JA: What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis. 2001;32 Suppl 1:S39-S46.
14. Davis RL, Koup JR, Williams-Warren J, Weber A, Heggen L, Stempel D, and Smith AL: Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother. 1987;31:915-919.
15. Lettieri JT, Rogge MC, Kaiser L, Echols RM, and Heller AH: Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 1992;36:993-996.
16. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, and Grasemann H: Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother. 2006;57:306-311.
17. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, and Ramsey BW: Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002;122:219-226.